HealthBio

What HealthBio does

HealthBio is a private, commercial-stage biotechnology company founded in 2020 by Dr. Bruce Patterson (former Stanford Associate Professor of Pathology and Infectious Diseases) and headquartered in Hayward, California. The company operates a vertically integrated platform spanning patented diagnostics, a clinical-stage therapeutic, and remote patient monitoring, with the wholly-owned subsidiary IncellDx, Inc. providing single-cell diagnostic laboratory reagents. HealthBio targets chronic inflammatory diseases—primarily Long COVID/Post-Acute Sequelae of SARS-CoV-2 infection (PASC)—with future extension into ME/CFS, Chronic Lyme, Fibromyalgia, Oncology, Alzheimer's and autoimmune indications.

The company's core technical asset is the IncellKINE blood-based diagnostic assay, which applies random-forest machine learning classifiers to a 14-analyte cytokine/chemokine panel to identify immune signatures associated with CCR5/fractalkine-mediated vascular inflammation. The companion S1 Immune Panel Test detects persistent SARS-CoV-2 S1 protein in monocyte subsets up to 15 months post-infection. The therapeutic pipeline is anchored by a patented combination of Selzentry (maraviroc) and Lipitor (atorvastatin) targeting the monocytic-endothelial-platelet axis, accepted by the FDA in January 2024 for a randomized clinical trial under the 505(b)(2) pathway. A patented biometric wearable ("Incelligence") provides remote symptom and vital-sign monitoring to complete the diagnosis-to-treatment-to-management loop.

Commercially, HealthBio generates revenue across four streams: RUO diagnostic testing (IncellKINE, S1 panel), prescription therapeutics (currently trial-stage), hardware sales of the biometric wearable, and professional services via telemedicine/Patient Concierge. Distribution runs through a US-centric physician-network and lab-partner model, with international reach enabled by the April 2024 PeploBio partnership covering the UK and EU. GTM is sales-led, leaning on peer-reviewed publications and physician education rather than direct-to-consumer advertising, the latter having drawn a UK ASA enforcement action for unsubstantiated disease-treatment claims.

Name

HealthBio

Legal name

HealthBio Inc

Website

https://healthbioai.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

HealthBio is a private commercial-stage biotech developing AI-driven diagnostic tests, a clinical-stage maraviroc/atorvastatin therapeutic, and a biometric wearable to diagnose and treat Long COVID and other chronic inflammatory diseases, serving patients and physicians primarily in the US with UK/EU expansion.

Ownership category

akta.pro rank

Product category

Diagnostic and Therapeutic Healthcare Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

Keywords

• Chronic inflammatory diagnostics
• Long covid treatment
• AI precision diagnostics
• Vascular inflammation therapeutics
• Immune-mediated disease diagnostics

Headquarters

HQ city

Hayward

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Diagnostic Testing Services: Blood-based diagnostic tests including IncellKINE and S1 Immune Panel tests processed through lab partners in USA and globally.
2. Pharmaceutical Treatment: Prescription therapeutic products (maraviroc/pravastatin combination) for treatment of Long COVID and other immune-mediated diseases through clinical trial and eventual commercialization.
3. Biometric Wearable Device: Remote patient monitoring device for tracking symptoms and health data.
4. Telemedicine Services: Virtual TeleMed consults and Patient Concierge Services platform.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

HealthBio is a commercial-stage biotechnology company that develops and sells AI-driven blood-based diagnostic tests (IncellKINE, S1 Immune Panel) and a patented drug combination (maraviroc/pravastatin) to diagnose and treat chronic inflammatory diseases, with a primary focus on Long COVID. Its offering combines diagnostics, prescription therapeutics, a biometric wearable monitoring device, and a telemedicine/Patient Concierge engagement platform.

Product overview

HealthBio offers a unified platform combining diagnostic testing, pharmaceutical treatment, and remote patient monitoring for chronic inflammatory diseases, with primary focus on Long COVID. The core portfolio includes: IncellKINE™ (RUO cytokine/chemokine diagnostic panel for identifying Long COVID immune signatures), the S1 Immune Panel Test (detecting SARS-CoV-2 S1 protein in monocytes), Selzentry/Lipitor combination therapy (FDA-accepted 505(b)(2) clinical trial for Long COVID treatment), biometric monitoring wearable device, and telemedicine engagement services. The subsidiary IncellDX provides single-cell diagnostic laboratory reagents across multiple regulatory classes (RUO, GPR, ASR, CE-IVD, US-IVD) for research and clinical applications including HPV, CMV, and cancer diagnostics. All components are designed to work together within HealthBioAI's machine learning and AI health data platform to provide a comprehensive path from diagnosis to treatment to management.

Differentiator

Problem solved

Functional benefit

Brands

• IncellKINE: Blood-based diagnostic assay designed to detect immune signatures for Long COVID and other immune-mediated diseases including ME-CFS and chronic Lyme.
• IncellDX
• Incelligence

Products and services

• IncellKINE™ Blood-based diagnostic assay that uses machine learning to measure and analyze cytokine/chemokine panels (IL-6, IFN-gamma, IL-2, IL-4, CXCL8, IL-10, IL-13, GM-CSF, CCL3, CCL4, CCL5, VEGF, TNF-alpha, sCD40L) to identify immune signatures for Long COVID and other immune-mediated diseases.
• S1 Immune Panel Test Blood test that detects SARS-CoV-2 S1 protein in monocytes resulting from either COVID-19 vaccine or natural infection. Includes CD3, CD4, and CD8 percentage and absolute count, plus monocyte subset percentage with and without S1 protein across classical, non-classical, and intermediate monocytes.
• Selzentry (maraviroc) + Lipitor (atorvastatin) Combination Patented prescription drug combination for treating Long COVID/Post Acute Sequelae of COVID (PASC). Maraviroc (CCR5 antagonist) and pravastatin/atorvastatin (fractalkine inhibitor) disrupt the monocytic-endothelial-platelet axis, reducing vascular inflammation and restoring immune homeostasis.
• Biometric Remote Monitoring Wearable (Incelligence) Patented biometric wearable device for immune health and wellness monitoring. Features 7-10 day battery life, 5 ATM water resistance, tracks vital health functions, 30-day data memory, and syncs with iPhone and Android devices. Allows symptom input and sharing with healthcare providers.
• Patient Concierge Services / TeleMed Platform Virtual healthcare engagement platform providing trained physicians and nurses for optimal patient engagement via TeleMed consultations and patient support services. Blood-based diagnostic tests are ordered through this channel.
• IncellDX Product Portfolio Single cell diagnostic laboratory reagents and kits across multiple regulatory classes (RUO, GPR, ASR, CE-IVD, US-IVD), including HPV E6/E7 mRNA Probe, CMV mRNA Probe, Hybridization Core Reagents, incellMAX Fix/Permeabilizer, Cell Cycle Dye, CytoStat triCHROME, Anti PD-L1 Antibody, Anti CD45 Antibody, Anti Pan Cytokeratin, incellPREP Tissue Single Cell Suspension System, BioINK PD-L1 CTC Core Kit, and HPV OncoTect 3Dx CE-IVD Kit.

Quantifiable outcome

• SARS-CoV-2 S1 protein detected in non-classical monocytes in PASC patients up to 15 months post-infection (P=0.02)
• +1 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• PeploBiocoreChannel Partner/ Reseller/ Distributor · 10 April 2024PeploBio and IncellDX partnered to launch the First Long COVID test in the UK and EU markets. This partnership enables HealthBio/IncellDX diagnostic products to reach European patients through PeploBio's distribution network.
• IncellDXcoreStrategic or Co-development Partner · 10 April 2024IncellDX is a single cell diagnostic company and related entity to HealthBio. Effective June 7, 2024, all IncellDX Product, Quality and Policy documents are available within the HealthBio website. IncellDX provides the underlying technology platform for multiplex RNA in situ hybridization and diagnostic products including IncellKINE tests.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Vir Biotechnology: Clinical-stage immunology company developing therapeutics that engage the immune system to treat infectious diseases. Comparable to HealthBio's strategy of targeting immune pathways (CCR5/fractalkine) driven by viral antigens, with overlapping interest in post-viral inflammatory syndromes.
• Spectral Medical: Late-stage clinical company developing diagnostic and therapeutic approaches for immune-mediated conditions (sepsis, endotoxemia). Comparable to HealthBio's positioning of blood-based immune diagnostics paired with targeted therapy for systemic inflammatory disease.
• Natera: Molecular diagnostics company specializing in cell-free DNA and immune-related testing. Comparable to HealthBio/IncellDX's molecular and single-cell diagnostic reagent portfolio, particularly in the infectious disease and immune phenotyping categories.
• Tempus AI: AI-driven precision medicine company that uses machine learning on multi-modal clinical and molecular data to support diagnostics and therapeutic decisions. Comparable to HealthBio's AI/ML diagnostic platform approach, though Tempus is focused primarily on oncology rather than chronic inflammatory disease.
• BioVie: Clinical-stage company developing therapies for Long COVID and neurodegenerative disease, including the drug BIV201. A direct therapeutic peer to HealthBio's Long COVID treatment program with maraviroc, pursuing a similar first-mover positioning in an underserved indication.
• Adaptive Biotechnologies: Immune profiling company using sequencing and ML to read T-cell and B-cell receptor repertoires for diagnostic and therapeutic applications. Comparable to HealthBio's immune-signature diagnostic thesis and ML-based classification approach for immune-mediated disease.
• PureTech Health: Clinical-stage biotherapeutics company with a Long COVID program (LYT-100/deupirfenidone) targeting post-viral inflammatory conditions. A direct therapeutic peer competing in the same Long COVID development space with a different mechanism of action.

Broad incumbents

• Quest Diagnostics: Major clinical diagnostics provider with extensive immunology, infectious disease, and specialty testing menus. Overlaps with HealthBio's diagnostic testing model for cytokine panels, immune phenotyping, and SARS-CoV-2-related assays, though Quest serves a much broader menu of routine and esoteric tests.
• LabCorp: One of the largest clinical laboratory networks in the US, offering blood-based diagnostic testing across thousands of analytes. Directly comparable to HealthBio's IncellKINE diagnostic testing service model and lab partner infrastructure, though at vastly greater scale and breadth.
• Foundation Medicine (Roche): Subsidiary of Roche providing comprehensive genomic profiling and molecular diagnostics, primarily for oncology. Comparable to IncellDX's single-cell diagnostic platform and PD-L1/HPV reagent portfolio, with significantly broader scale and integration into pharma R&D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/in/bruce-patterson-2bb84427

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HealthBio